Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
StimuSIL Hair Growth Device Trial Listed On ClinicalTrials.Gov
Recently, you may have read about the newcomer device company, StimuSIL, on Follicle Thought. StimuSIL has created an innovation upon LLLT therapy with the hopes to create a treatment which is not only utilized, but respected, in the hair growth world. The first step in achieving that goal is to run a successful human clinical trial, which StimuSIL has embarked upon. A new listing on ClinicalTrials.gov reveals previously unknown details about the company's device.
New information about the StimuSIL SAGA device and trial format:
- Two device versions, SAGA-001 (A) and SAGA-001 (B) are being trialed.
- 38 adult males with androgenetic alopecia comprise the testing pool.
- Patients will receive 8 treatments over the course of 4 months (bi-weekly treatment).
- Primary outcome is the measured change in terminal hair density.
Carmell Therapeutics PRP Without Blood Draw
Earlier this week, Follicle Thought formally introduced a company developing an off the shelf version of platelet rich plasma for hair growth injections. Carmell Therapeutics is based in Pennslyvania, US and is planning to enter a large animal preclinical trial within the next several months. A clinical trial could follow shortly thereafter. Check the full Article for more information.
Another Drug Approved For Alopecia Areata: Litfulo Ritlecitinib
In June 2023, the US FDA approved its second oral drug against alopecia areata, ritlecitinib. This kinase inhibitor blocks JAK 3 and tyrosine kinase which creates a therapeutic effect on auto-immune disorders. The drug will be branded as Litfulo and is intended to treat severe alopecia areata in people above the age of 12. Eli Lilly's Olumiant, which became the first approved oral drug for AA back in June 2022, is only approved for adults.
Kintor KX-826 Pyrtilutamide Phase 3 Trial Approval Delayed?
On July 19, 2023, Kintor Pharmaceutical announced the first patient enrollment in a new long-term safety phase III trial of KX-826 in AGA in China. Note, this is in addition to the phase 3 trial for male AGA which began in January 2022 in China. The new phase 3 trial will evaluate the long-term safety and efficacy of KX-826 in males and females over the course of a 52 week dosing period and will include 270 subjects. It may be the case that the Chinese regulatory agency requested that Kintor complete a longer phase 3 trial than the original 24 week trial which began last year. At this time, it appears that the potential approval timeline for KX-826/pyrilutamide may be pushed back until the completion of the latest safety phase 3 trial.
Mallia Therapeutics Raises Funds For CD83 Hair Growth Therapy
Head to the Articles page to read the new writeup on Mallia Therapeutics' latest developments for soluble CD83 (sCD83). Mallia Therapeutics (formerly MalliaBiotech) have also unveiled a new website which is linked in the article.
Life Code WCD2023 Poster
Life Code, a company participating in the World Congress of Dermatology Singapore 2023, recently shared a poster displaying hair growth data with Follicle Thought. The company uses an artificial intelligence drug discovery platform called PetaPoly to find new molecules for various biological conditions. Life Code found a molecule called LCH34 for hair growth purposes. Check the main Articles page to view Life Code's poster.
Amplifica Announces New Compound AMP-303
Amplifica has been very active in the first half of 2023. They announced the addition of SCUBE 3 (AMP-601) to their pipeline back in January, and announced osteopontin (AMP-203) in June as another compound discovered from Maksim Plikus' research into hairy moles and hair growth. Now, just a week after the AMP-203 announcement, Amplifica has issued a press release for the initiation of a clinical trial for new mystery compound AMP-303. The front page and Articles page has the full Amplifica story.
StimuSIL: Injecting Laser Therapy Subdermally
StimuSIL is medical device startup based in Europe which has developed a patented, proprietary technology which allows laser therapy to reach beneath the skin's surface. The company intends to stimulate hair follicles beneath the melanin layer with laser light and through other means to achieve improved results. Recently, StimuSIL has initiated a multi-center clinical trial to gauge the efficacy of their device.
Our affiliated feature on StimuSIL: StimuSIL's SAGA-001: A New Paradigm in Laser Therapy For Hair Loss
StimuSIL is putting on a webinar for potential investors, patients, and anyone who is interested in learning more about their technology, clinical trials, and pathway ahead. Register for the webinar below. (This is not financial advice)
Update: The webinar has been postponed.
Everyone who signed up for the webinar, like myself, was contacted and informed that the webinar was postponed due to StimuSIL’s CMO Dr. Gerrish encountering a last minute flight delay. The current date for rescheduling is Thursday, July 13th, at 1 PM EST.
Register here ✍: Webinar Sign Up Form
Amplifica Shares Hairy Moles Hair Growth Update
Amplifica, the California biotech founded by Drs. Maksim Plikus and William Rassman, announced today the imminent start of a clinical trial for one of the company's pipeline drugs. Having previously discussed SCUBE3 (a signaling molecule) in the media, today Amplifica announced its research into osteopontin, another protein involved in the "hairy mole" phenomenon. To summarize, over the past several years, Dr. Maksim Plikus has been studying human skin moles and has sought to elucidate why moles tend to grow strong terminal hairs even when they are located on skin which would not typically grow such type of hairs. Dr. Plikus has identified several molecules involved in this process including SCUBE3, osteopontin, and others and is currently working to translate his findings into clinical therapies. Plikus' media commentary today stated that Amplifica is intending to begin a clinical trial for osteopontin scalp injections before the end of the summer, and that the treatment would be similar to botox injections.
OliX Pharmaceuticals Begins Human Trial For RNAi Drug
Today, OliX Pharmaceuticals announced the first patient has been dosed in its phase 1 clinical trial of drug candidate OLX72021 in treating androgenic alopecia. From today's release, the trial will include 30 males divided into 5 cohorts who will receive an injection of OLX72021 or placebo. OliX's drug works to silence or prevent the expression of the androgen receptor, which is an approach we have recently seen in the global pharma setting. Distinctively, OliX's OLX72021 is proposed to be an injectable therapy rather than topical. Only time will tell the potential benefits or subtractions from using injection as the treatment modality. Finally, OliX Pharmaceuticals reiterated its intent to create hair loss cosmeceuticals in today's announcement.